Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia

Circulation: Heart Failure

Volumn 4, Issue 5, 2011, Pages 637-643

  Madan, Vinay D ^a   Novak, Eric ^a   Rich, Michael W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Hyponatremia; Prognosis

Indexed keywords

SODIUM; UREA; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SODIUM BLOOD LEVEL; SURVIVAL; UREA NITROGEN BLOOD LEVEL; BLOOD; COMORBIDITY; HOSPITAL PATIENT; KAPLAN MEIER METHOD; MIDDLE AGED; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPONATREMIA; INPATIENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM; SURVIVAL RATE;

EID: 84856394054     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.961011     Document Type: Article

References (25)

1. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am. 2003;32:459-481. (Pubitemid 36666228)
2. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30-S35.
3. Gheorghiade M, Gattis WA, O'Connor CM, Kirkwood KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971. (Pubitemid 38544277)
4. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, for the Tolvaptan Investigators. Vasopressin V2-receptor blockade with Tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial. Circulation. 2003;107:2690-2696. (Pubitemid 36667242)
5. Konstam, MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. JAMA. 2007;297:1319-1331.
6. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332-1343. (Pubitemid 46513234)
7. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusuf S, for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724-1729. (Pubitemid 20367975)
8. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390. (Pubitemid 13054124)
9. Rossi J, Orlandi C, Gheorghiade M. Vasopressin antagonists in the management of heart failure. Expert Rev Cardiovasc Ther. 2007;5:323-330. (Pubitemid 46488145)
10. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohormonal activation and responses to orthostasis. J Clin Endocrinol Metab. 1984;59:924-930. (Pubitemid 14020694)
11. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257-267. (Pubitemid 16127402)
12. Krumholz HM, Chen YT, Bradford WD, Cerese J. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care. 2006;5:715-723.
13. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, Eckberg DL, Zaman AG, Williams S, Neilson JMM, Nolan J. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;50:1801-1808. (Pubitemid 35341959)
14. Rich MW, Beckham V, Wittenberg, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-1195.
15. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587. (Pubitemid 37443288)
16. Georghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, Fonarow GC, De Marco T, Pauly DF, Rogers J, Di Salvo TG, Butler J, Hare JM, Francis GS, Gattis-Stough W, O'Connor CM. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007;167:1998-2005. (Pubitemid 47606641)
17. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF, Califf RM, Gheorghiade M, for the OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460. (Pubitemid 40696133)
18. Gheorghiade M, Abraham WT, Albert NM, Gattis-Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC, on behalf of the OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980-988. (Pubitemid 47343897)
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
20. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31:1402-1415. (Pubitemid 17090506)
21. Rossi J, Bayram M, Udelson J, Lloyd-Jones D, Adams KF, O'Connor CM, Gattis-Stough W, Ouyang J, Shin DD, Orlandi C, Gheorghiade M. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care. 2007;9:82-86. (Pubitemid 46955230)
22. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M, for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547. (Pubitemid 34269999)
23. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE trial. JAMA. 2005;294:1625-1633. (Pubitemid 41407355)
24. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation. 2008;118:410-421.
25. The BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation. http://clinicaltrials. gov/ct2/show/NCT00578695. Accessed May 16, 2011.